PMID- 15707852
OWN - NLM
STAT- MEDLINE
DCOM- 20050524
LR  - 20151119
IS  - 1094-5539 (Print)
IS  - 1094-5539 (Linking)
VI  - 18
IP  - 3
DP  - 2005
TI  - Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary 
      hypertension.
PG  - 181-6
AB  - Selective pulmonary vasodilators attenuate acute pulmonary embolism (APE)-induced 
      pulmonary hypertension. We examined the effects of intravenous sildenafil on the 
      hemodynamic and respiratory changes caused by APE in anesthetized dogs. Sham 
      operated animals (n=3) received only saline infusions. APE was induced by 
      intravenous injections of microspheres in amounts adjusted to increase mean 
      pulmonary artery pressures (MPAP) by 20 mmHg. Hemodynamic evaluation was 
      performed and arterial blood samples were drawn for blood gas analysis at 
      baseline, 15 and 30 min after APE was induced, and then 15, 30, and 45 min after 
      the sildenafil infusion (1 mg kg(-1) infused intravenously in 15 min followed by 
      0.3 mg kg(-1) h(-1) for 30 min) started in the Sildenafil group (n=7), or saline 
      infusion started in the control group (n=8). APE induced sustained pulmonary 
      hypertension and 325% increase in pulmonary vascular resistance index (PVRI) 
      without significant changes in the other hemodynamic parameters. While the 
      animals in the control group showed no further changes in MPAP and PVRI, a 
      significant decrease in MPAP and PVRI (-25 and -45%, respectively; P<0.05 both) 
      was observed with sildenafil. No significant changes in the other hemodynamic 
      parameters were observed in both groups. APE decreased PaO2, whereas sildenafil 
      attenuated the decrease in PaO2 (P<0.05). We conclude that intravenous sildenafil 
      can selectively attenuate the increases in MPAP and PVRI after APE.
FAU - Dias-Junior, Carlos A
AU  - Dias-Junior CA
AD  - Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of 
      Sao Paulo, Av. Bandeirantes, 3900, 14049-900 Ribeirao Preto, SP, Brazil.
FAU - Vieira, Tadeu F
AU  - Vieira TF
FAU - Moreno, Heitor Jr
AU  - Moreno H Jr
FAU - Evora, Paulo R
AU  - Evora PR
FAU - Tanus-Santos, Jose E
AU  - Tanus-Santos JE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050120
PL  - England
TA  - Pulm Pharmacol Ther
JT  - Pulmonary pharmacology & therapeutics
JID - 9715279
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - BW9B0ZE037 (Sildenafil Citrate)
SB  - IM
MH  - Animals
MH  - Dogs
MH  - Female
MH  - Heart Rate/drug effects
MH  - Hypertension, Pulmonary/*etiology
MH  - Infusions, Intravenous
MH  - Male
MH  - Phosphodiesterase Inhibitors/*therapeutic use
MH  - Piperazines/*therapeutic use
MH  - Pulmonary Embolism/complications/*drug therapy
MH  - Purines
MH  - Sildenafil Citrate
MH  - Sulfones
MH  - Vascular Resistance/drug effects
EDAT- 2005/02/15 09:00
MHDA- 2005/05/25 09:00
CRDT- 2005/02/15 09:00
PHST- 2004/04/08 00:00 [received]
PHST- 2004/11/22 00:00 [revised]
PHST- 2004/11/27 00:00 [accepted]
PHST- 2005/02/15 09:00 [pubmed]
PHST- 2005/05/25 09:00 [medline]
PHST- 2005/02/15 09:00 [entrez]
AID - S1094-5539(04)00159-2 [pii]
AID - 10.1016/j.pupt.2004.11.010 [doi]
PST - ppublish
SO  - Pulm Pharmacol Ther. 2005;18(3):181-6. doi: 10.1016/j.pupt.2004.11.010. Epub 2005 
      Jan 20.